Patents by Inventor Jason Cameron
Jason Cameron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160222087Abstract: The present invention relates to variants of a parent albumin; the variants comprise one or more mutations in Domain II of albumin which lead to a change in binding affinity to FcRn and/or a change in half-life compared to the “parent” albumin. The invention allows tailoring of binding affinity and/or half-life of an albumin to the requirements and desires of a user or application. The invention also relates to fragments and fusion polypeptide of the variant albumins, as well as to polynucleotides encoding the variants, nucleic acid constructs, vectors, host cells comprising the polynucleotides and methods of using said variants.Type: ApplicationFiled: September 12, 2014Publication date: August 4, 2016Applicant: Novozymes Biopharma DK A/SInventors: Karen DELAHAY, Jason CAMERON
-
Patent number: 9403898Abstract: An improved method for purifying albumin, a variant or fragment thereof, a fusion protein comprising albumin, a variant or fragment thereof, or a conjugate comprising albumin, a variant or fragment thereof is disclosed.Type: GrantFiled: May 7, 2010Date of Patent: August 2, 2016Assignee: NOVOZYMES BIOPHARMA DK A/SInventors: Lee Edward Blackwell, Jason Cameron, Phillip Harvey Morton, Steven James Burton, Richard Anthony Dodd, Mark Jonathan Burton
-
Publication number: 20160075758Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: September 24, 2015Publication date: March 17, 2016Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20160075762Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: September 24, 2015Publication date: March 17, 2016Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20160075759Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: September 24, 2015Publication date: March 17, 2016Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20160075756Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: September 24, 2015Publication date: March 17, 2016Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20160075761Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: September 24, 2015Publication date: March 17, 2016Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20160075757Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: September 24, 2015Publication date: March 17, 2016Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20160075760Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: September 24, 2015Publication date: March 17, 2016Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20160075763Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: September 24, 2015Publication date: March 17, 2016Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Patent number: 9279951Abstract: A fiber optic module having a module housing and a module sub-assembly. The module housing defines at least an interior space, at least one adapter aperture and at least one input aperture. The module sub-assembly defines at least one fiber optic cable, for example, passing through the at least one input aperture, at least one multi-fiber connector on an end of the fiber optic cable, and at least one single fiber connector on an opposite end of the fiber optic cable, the multi-fiber connector being in optical communication with the at least one single fiber connector, the multi-fiber connector capable of flexing on the at least one fiber optic cable relative to the module housing.Type: GrantFiled: October 26, 2011Date of Patent: March 8, 2016Assignee: Corning Cable Systems LLCInventors: Daniel Scott McGranahan, Kenneth Charles Simonson, Jason Cameron Payne
-
Publication number: 20160033523Abstract: The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for HSA binding to the FcRn receptor in said animal. In the non-primate animal species, the binding affinity of wild type HSA to the native FcRn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native FcRn. The present invention also relate to animal models which are particularly suitable for assessing pharmacokinetics of human serum albumin variants.Type: ApplicationFiled: February 14, 2014Publication date: February 4, 2016Inventors: Jason Cameron, Darrell Sleep, Jan Terje Andersen, Inger Sandlie
-
Publication number: 20160009787Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: September 24, 2015Publication date: January 14, 2016Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20150210752Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: April 13, 2015Publication date: July 30, 2015Inventors: Jason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
-
Patent number: 9029102Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilized aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.Type: GrantFiled: July 1, 2011Date of Patent: May 12, 2015Assignee: Novozymes Biopharma DK A/SInventors: Hendrik Van Urk, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michael Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Jean-Luc Bernard Veron
-
Publication number: 20150056654Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilised aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.Type: ApplicationFiled: July 14, 2014Publication date: February 26, 2015Inventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michael Gaston Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-luc Bernard Veron
-
Patent number: 8891930Abstract: A fiber management frame for a fiber optic closure having a removable tray holder configured to mount a fiber optic tray offset from a fiber management interface. The tray holder has optical fibers mounted thereon and can be mounted and/or removed from the fiber management interface without interfering with optical fibers mounted on the fiber management interface. The fiber management interface defines a first slack storage area for a first group of optical fibers. The removable tray holder defines a second slack storage area for a second group of optical fibers offset from the fiber management interface. The fiber optic tray can be mounted to or removed from the fiber management interface without interfering with the first group of optical fibers.Type: GrantFiled: May 30, 2013Date of Patent: November 18, 2014Assignee: Coring Cable Systems LLCInventors: Salvador Anguiano, Jason Cameron Payne, Karyne Poissant Prevratil, John Joseph Stillwell
-
Publication number: 20140315816Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Patent number: 8822417Abstract: Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.Type: GrantFiled: May 4, 2012Date of Patent: September 2, 2014Assignee: Novozymes Biopharma DIC A/SInventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Publication number: 20140234311Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis